Wasserstein, Melissa P.
Caggana, Michele
Bailey, Sean M.
Desnick, Robert J.
Edelmann, Lisa
Estrella, Lissette
Holzman, Ian
Kelly, Nicole R.
Kornreich, Ruth
Kupchik, S. Gabriel
Martin, Monica
Nafday, Suhas M.
Wasserman, Randi
Yang, Amy
Yu, Chunli
Orsini, Joseph J.
Article History
Received: 12 March 2018
Accepted: 27 June 2018
First Online: 10 August 2018
Disclosure
: Melissa Wasserstein has served as a consultant for and has received travel reimbursement from Sanofi Genzyme. Robert J. Desnick is a consultant for Amicus Therapeutics, Sanofi Genzyme, and Sangamo Therapeutics. He has received research grants from Sanofi Genzyme and Sangamo Therapeutics. He owns founder's shares for Amicus Therapeutics and options for Sangamo Therapeutics. He has patents for Fabry and Niemann–Pick treatments and receives royalties from Sanofi Genzyme. Lisa Edelmann is an employee of Sema4, a for-profit genetic testing laboratory. Ruth Kornreich is an employee of Sema4, a for-profit genetic testing laboratory. Amy Yang has served as a consultant for Shire Therapeutics. Chunli Yu is an employee of Sema4, a for-profit genetic testing laboratory. The other authors declare no conflicts of interest.